| Clonal Hematopoiesis, Inflammation, and Hematologic Malignancy |
|
Annual Review of Pathology: Mechanisms of Disease |
Aplastic Anemia, Myelodysplastic Syndromes (MDS), Paroxysmal Nocturnal Hemoglobinuria (PNH) |
| Standardization of Bone Marrow Reporting for Myelodysplastic Syndromes/Neoplasms on Behalf of the International Consortium for Myelodysplastic Syndromes/Neoplasms |
|
Archives of Pathology & Laboratory Medicine |
Myelodysplastic Syndromes (MDS) |
| MDS/MPN-RS-T Justified Inclusion as a Unique Disease Entity? |
|
Best practice & research. Clinical haematology |
Myelodysplastic Syndromes (MDS), Myeloproliferative Neoplasms (MPN) |
| Establishing Specific Response Criteria for MDS/MPN - Getting Closer to Reality? |
|
Best practice & research. Clinical haematology |
Myelodysplastic Syndromes (MDS), Myeloproliferative Neoplasms (MPN) |
| Randomized trials with checkpoint inhibitors in acute myeloid leukaemia and myelodysplastic syndromes: What have we learned so far and where are we heading? |
|
Best practice & research. Clinical haematology |
Myelodysplastic Syndromes (MDS) |
| Myelodysplastic/myeloproliferative Neoplasm, Unclassifiable (MDS/MPN-U): More Than Just a "Catch-All" Term? |
|
Best practice & research. Clinical haematology |
Myelodysplastic Syndromes (MDS), Myeloproliferative Neoplasms (MPN) |
| Establishing Specific Response Criteria for MDS/MPN - Getting Closer to Reality? |
|
Best practice & research. Clinical haematology |
Myelodysplastic Syndromes (MDS) |
| Clonal Hematopoiesis and therapy related MDS/AML |
|
Best Practice & Research. Clinical Heamatology |
Myelodysplastic Syndromes (MDS) |
| The Path to Accessible Care: Development and Impact of Eculizumab Biosimilars for Paroxysmal Nocturnal Hemoglobinuria and Atypical Hemolytic Uremic Syndrome |
|
BioDrugs |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
| Consider Allogeneic Bone Marrow Transplantation for Older, Fit Patients with Aplastic Anemia |
|
Biol Blood Marrow Transplant |
Aplastic Anemia |
